Skip to main content

Genomic Tests Ready For Primetime?

 
8/4/2010:
 
Hello everyone, I am Dr. Muin Khoury, director of the Office of Public Health Genomics at the Centers for Disease Control and Prevention.
You may have heard about different tests. You may even have had patients ask you about these tests or share the results with you.

So why aren't personal genomic tests ready for primetime?

There are 3 key factors that must be considered in the development and evaluation of genetic tests in clinical practice. First, there is the test's analytic validity, which is the test's ability to accurately and reliably measure the thousands of genetic variants on these tests.

In many cases, personal genomic tests do meet quality standards for laboratories. The second thing we have to look at is the clinical validity of these tests, which is the ability of the test to detect or predict particular diseases and health conditions. This is the area for which the data are in so much flux right now.

Most common diseases, as a matter of fact, like diabetes, cancers, and heart disease, are caused by multiple genes and interactions with environment and behavior. More research is needed to identify the full list of variants and how they influence disease susceptibility.

So far, a simple knowledge of family history for disease seems to be a more important risk factor for most common diseases. Genetic variants associated with diseases that have been identified so far typically account for only a small fraction of the measured impact of family history. Therefore, there is a lot of uncertainty about the risk estimates given by these tests; the estimates could rapidly change and [estimates] also vary by patient characteristics such as age, race and ethnicity, and environmental and lifestyle factors.

Finally, there is the most critical issue of the test's clinical utility, which addresses the question of: if a patient is found to be at increased or decreased risk for a disease, what can be done about it? In this area, there is virtually no information available that looks at the health implications of communicating genomic information and the balance of benefits and harms for using these types of tests.


So what advice should providers offer patients?

First, discuss with patients the limitations of personal genomic tests. These tests are not ready for routine use in clinical practice because of their limited clinical validity and clinical utility. Second, encourage patients to collect and keep an updated family health history. Family health history is a very informative and inexpensive "genomic test" that can be used right now. It reflects genes, behaviors, lifestyles, and environmental factors that are shared among relatives..

Family health history can help healthcare providers assess the presence of many genetic conditions and whether patients and their relatives may have an increased risk for specific diseases

And lastly, use the discussion of personal genomic tests and family history as a teachable moment to encourage patients to improve their health. We can reinforce the value of simple health promotion and disease prevention messages about increased physical activity, avoidance of cigarette smoking, improved diet, as well as adoption of medical screenings to help lower risk for specific common diseases regardless of genes.

The promise of genomics in the practice of medicine is great and exciting, but today the use of personal genomic tests is still not ready for prime time.

Thank you for your attention.

Web Resources

Genetic Testing, CDC Office of Public Health Genomics http://www.cdc.gov/genomics/gtesting/index.htm
GeneTests. National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/sites/GeneTests/?


Comments

Popular posts from this blog

Get the Facts About Genetic Colon Cancer

Get the Facts: http://genefacts.org Lynch syndrome is a cancer predisposition syndrome caused by inherited mutations in genes responsible for correcting DNA replication errors. Individuals with Lynch syndrome have a greatly increased risk for colorectal, endometrial, and stomach cancers, and a moderately increased risk for other cancers. Key Points 1-3% of colon cancers attributable to Lynch syndrome Dominant inheritance with reduced penetrance (not all patients with mutations will manifest disease) Diagnosis based on clinical and family history, tumor pathology and/or genetic testing Screening and prophylactic surgeries effective in reducing some, but not all cancer risks Mutations in any of several genes can cause the syndrome

Cancer Survivors

Just read a story about one woman's cancer experience. I bet everyone has a story about what goes through your mind when you are told you have cancer. Her thought were about her stunned family members, one crying and the other in shock. I bet there are quite a few stories that could be qualitatively studied. Those experiences could help nurses better help patients during this time.

My Publication, "Hereditary non-polyposis colon cancer: change the name to protect the innocent." Cited in World Journal of Gastroenterology

Estradiol agonists inhibit human LoVo colorectal-cancer cell proliferation and migration t... Hsi-Hsien Hsu, Wei-Wen Kuo, Da-Tong Ju... World journal of gastroenterology : WJG 11/2014 20(44):16665-73. World Journal of Gastroenterology : WJG 11/2014; 20(44):16665-73. DOI: 10.3748/wjg.v20.i44.16665 Source: PubMed ABSTRACT To investigate the effects of 17β-estradiol via estrogen receptors (ER) or direct administration of ER agonists on human colorectal cancer. LoVo cells were established from the Bioresource Collection and Research Center and cultured in phenol red-free DMEM (Sigma, United States). To investigate the effects of E2 and/or ER selective agonists on cellular proliferation, LoVo colorectal cells were treated with E2 or ER-selective agonists for 24 h and 48 h and subjected to the MTT (Sigma) assay to find the concentration. And investigate the effects of E2 and/or ER selective agonists on cell used western immunoblotting to find out the diver...